F S&P 500
5,243.00 -2.50 (-0.05%) F Dow Jones
39,555.00 -4.00 (-0.01%) F Nasdaq
18,275.00 -20.50 (-0.11%) E-mini Russell 2000 Index Futur
2,071.40 -1.10 (-0.05%) Petróleo
79.15 +0.03 (+0.04%) Oro
2,345.60 +2.60 (+0.11%)
SciSparc Ltd. (SPRC)
Fuera de horario:
SciSparc Ltd.
Tower A
2nd Floor 20 Raul Wallenberg Street
Tel Aviv 6971916
Israel
972 7 334 47180
https://scisparc.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 3
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Oz Adler CPA | CEO & CFO | 363k | N/D | 1987 |
| Mr. Itschak Shrem | President & Director | 219k | N/D | 1947 |
| Dr. Adi Zuloff-Shani Ph.D. | Chief Technologies Officer | 274k | N/D | 1969 |
Descripción
SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation; SCI-160 for the treatment of pain; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution. The company has an agreement with Procaps to develop and commercially manufacture SCI-110 and CannAmide, a palmitoylethanolamide oral tablet in softgel capsule form. It also has an agreement with The Israeli Medical Center for Alzheimer's to conduct a phase IIa clinical trial to evaluate the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer's disease and agitation; and a collaboration with Clearmind Medicine Inc. The company was formerly known as Therapix Biosciences Ltd. and changed its name to SciSparc Ltd. in January 2021. SciSparc Ltd. was incorporated in 2004 and is headquartered in Tel Aviv-Yafo, Israel.
Gestión corporativa
La calificación ISS Governance QuickScore de SciSparc Ltd. a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.
